Abstract:ObjectiveTo study the efficacy of Ticagrelor and ezetimibe in the treatment of elderly patients with acute ST-elevation myocardial infarction (STEMI) and the value of preventing major adverse cardiovascular events (MACE) after the patients undergoing percutaneous coronary intervention (PCI). MethodsA total of 120 elderly STEMI patients receiving PCI in the First Peoples Hospital of Foshan from January 2016 to January 2021 were selected and were randomly divided into observation group and control group (n=60, each). Based on the conventional treatment in both groups, ticagrelor was used in control group, and ezetimibe with ticagrelor was given in observation group. MACE and adverse reactions were collected after PCI, levels of Interleukin（IL）-6, procalcitonin (PCT) and high-sensitivity C-reactive protein (hs-CRP) were detected, and left ventricular end diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF) were measured. ResultsBefore operation, TIMI myocardial perfusion grade(TMPG) of patients in observation group was better than that in control group (P<0.05), and there was no significant difference in it after operation between two groups (P>0.05).Compared with those in control group, the operation time and the incidence of MACE （11.67% vs28.33%) significantly decreased in observation group (P<0.05). The incidence of adverse reactions was similar in the two groups (P>0.05). After 3 months of treatment, IL-6, PCT and hs-CRP levels and LVEDD decreased, and LVEF increased in observation group compared with those in control group (P<0.05). ConclusionTicagrelor combined with ezetimibe can reduce the incidence of MACE and the inflammatory response, improve the cardiac function and have a good clinical application value in elderly STEMI patients after PCI.